Sökning: onr:"swepub:oai:DiVA.org:uu-453397" >
Antiproliferative S...
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours
-
- Dawod, Mohammed (författare)
- Christie NHS Fdn Trust, Ctr Excellence, ENETs, Dept Med Oncol, Manchester, Lancs, England
-
- Alonso Gordoa, Teresa (författare)
- Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain
-
- Cives, Mauro (författare)
- Univ Bari, Dept Med Oncol, Bari, Italy
-
visa fler...
-
- De Mestier, Louis (författare)
- Univ Paris, Beaujon Hosp, Dept Gastroenterol, Clichy, France
-
- Crona, Joakim (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Spada, Francesca (författare)
- European Inst Oncol, Gastrointestinal Med Oncol & Neuroendocrine Tumor, Milan, Italy
-
- Oberg, Kjel (författare)
- Univ Klinikum Erlangen, Dept Endocrinol, Erlangen, Germany
-
- Pavel, Marianne (författare)
- Univ Manchester, Christie NHS Fdn Trust, Ctr Excellence, ENETs,Dept Med Oncol, Div Canc Sci, Manchester, Lancs, England
-
- Lamarca, Angela (författare)
- Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England
-
visa färre...
-
(creator_code:org_t)
- 2021-06-29
- 2021
- Engelska.
-
Ingår i: Current Treatment Options in Oncology. - : Springer Nature. - 1527-2729 .- 1534-6277. ; 22:8
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with rising incidence and prevalence. Outcome and therapy of small bowel neuroendocrine tumours (SBNETs) is variable, depending on the grade, differentiation, tumour burden, as well as the site of the tumour origin. Because of this, multidisciplinary approach is essential. Large randomized clinical trials, with somatostatin analogues (PROMID, CLARINET) or with peptide receptor radionuclide therapy (PRRT) with 177-lutetium (NETTER-1 trial) as well as the mammalian target of rapamycin inhibitor (mTOR) everolimus (RADIANT trials), represent milestones for the medical management of unresectable grade 1 and 2 SBNETS over the last decade. Novel therapies, such as tyrosine kinase inhibitors (TKI), are on the cutting edge. However, multiple unsolved questions remain. This review provides a comprehensive review of the main systemic therapeutic options for advanced SBNETs and discusses the latest guideline recommendations for palliative treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Small bowel neuroendocrine tumour
- Well-differentiated
- Somatostatin analogue
- PRRT
- Third-line treatment
- Progression
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas